GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Margin of Safety % (DCF FCF Based)

CHGCF (Chugai Pharmaceutical Co) Margin of Safety % (DCF FCF Based) : 36.82% (As of Dec. 12, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2024-12-12), Chugai Pharmaceutical Co's Predictability Rank is 3-Stars. Chugai Pharmaceutical Co's intrinsic value calculated from the Discounted FCF model is $74.13 and current share price is $42.43. Consequently,

Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based) using Discounted FCF model is 36.82%.

Competitive Comparison of Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based)

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based) falls into.


Chugai Pharmaceutical Co Margin of Safety % (DCF FCF Based) Calculation

Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(67.16-42.43)/67.16
=36.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

Chugai Pharmaceutical Co Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Margin of Safety % (DCF FCF Based)
Comparable Companies
TSE:4568 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
CHGCY:USA 4519:Japan CUP:Germany
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Website
http://www.chugai-pharm.co.jp
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.